Physician profile
Frank Michael D'Alessandro
NPI 1225018955
$92,795.54
in general payments reported to CMS, 2019-2025
57 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,320 · 2021: $12K · 2022: $21K · 2023: $5,400 · 2024: $10K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $4,992 · Travel and Lodging: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,258.44 |
| Food and Beverage | $4,991.89 |
| Travel and Lodging | $1,031.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $82,737.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,241.14 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,119.24 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $809.79 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $798.38 | 2019-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $579.64 | 2019-2022 | |
| Amgen INC. | $463.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $443.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $423.15 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $312.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $289.70 | 2022-2024 | |
| Abbott Laboratories | $235.64 | 2022-2025 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $235.32 | 2019-2020 | |
| Inspire Medical Systems, INC. | $226.88 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $194.66 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank D'Alessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.